IV AAT
Graft-Versus-Host Disease (GvHD)
About Kamada
Kamada is a profitable, vertically integrated biopharmaceutical company with a mission to provide high-quality therapeutics for rare and serious conditions. The company has achieved record financial performance, driven by its commercial plasma-derived products, a robust development pipeline led by an inhaled Alpha-1 Antitrypsin candidate, and a strategic CDMO business. Its strategy is built on a three-pillar model: commercial execution, innovative R&D, and leveraging its industry-leading manufacturing capabilities for organic and partnership-driven growth.
View full company profileAbout Kamada
Kamada is a profitable, vertically integrated biopharmaceutical company with a mission to provide high-quality therapeutics for rare and serious conditions. The company has achieved record financial performance, driven by its commercial plasma-derived products, a robust development pipeline led by an inhaled Alpha-1 Antitrypsin candidate, and a strategic CDMO business. Its strategy is built on a three-pillar model: commercial execution, innovative R&D, and leveraging its industry-leading manufacturing capabilities for organic and partnership-driven growth.
View full company profileTherapeutic Areas
Other Graft-Versus-Host Disease (GvHD) Drugs
| Drug | Company | Phase |
|---|---|---|
| ABO21009 | AboleIIs Pharma | Preclinical |